Baseline Clinical and Biomarker Characteristics of Biobank Innovations for Chronic Cerebrovascular Disease With Alzheimer’s Disease Study: BICWALZS

키워드

참고문헌 (42)

1. Winblad B, "Defeating Alzheimer’s disease and other dementias: a priority for European science and society", Lancet Neurol, 15, pp.455~532 (2016)
2. Hardy J, "Alzheimer’s disease: where next for anti-amyloid therapies?", Brain, 140, pp.853~855 (2017)
3. Doody RS, "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease", N Engl J Med, 370, pp.311~321 (2014)
4. Schneider L, "A resurrection of aducanumab for Alzheimer’s disease", Lancet Neurol, 19, pp.111~112 (2020)
5. Kapasi A, "Impact of multiple pathologies on the threshold for clinically overt dementia", Acta Neuropathol, 134, pp.171~186 (2017)
6. Brenowitz WD, "Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample", Alzheimers Dement, 13, pp.654~662 (2017)
7. Dichgans M, "Vascular cognitive impairment", Circ Res, 120, pp.573~591 (2017)
8. van der Flier WM, "Vascular cognitive impairment", Nat Rev Dis Primers, 4, pp.18003~ (2018)
9. Ye BS, "Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia", Neurology, 85, pp.1687~1693 (2015)
10. Chui HC, "Cognitive impact of subcortical vascular and Alzheimer’s disease pathology", Ann Neurol, 60, pp.677~687 (2006)
11. Lee MJ, "Synergistic effects of ischemia and beta-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment", JAMA Psychiatry, 71, pp.412~422 (2014)
12. Chong JSX, "Amyloid and cerebrovascular burden divergently influence brain functional network changes over time", Neurology, 93, pp.e1514~e1525 (2019)
13. Palmqvist S, "Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures", Nat Med, 27, pp.1034~1042 (2021)
14. Penney J, "Modeling Alzheimer’s disease with iPSC-derived brain cells", Mol Psychiatry, 25, pp.148~167 (2020)
15. Rivetti di Val Cervo P, "hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible", Nat Rev Neurol, 17, pp.381~392 (2021)
16. Winblad B, "Mild cognitive impairment--beyond controversies, towards a consensus:report of the International Working Group on Mild Cognitive Impairment", J Intern Med, 256, pp.240~246 (2004)
17. McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
18. Sachdev PS, "Classifying neurocognitive disorders: the DSM-5 approach", Nat Rev Neurol, 10, pp.634~642 (2014)
19. 안현정, "Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients", Journal of Korean Medical Science, 25(7), pp.1071~1076 (2010), 대한의학회
20. Tzourio-Mazoyer N, "Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI singlesubject brain", Neuroimage, 15, pp.273~289 (2002)
21. Hwang J, "Clinical and biomarker characteristics according to clinical spectrum of Alzheimer’s Disease (AD) in the validation cohort of Korean brain aging study for the early diagnosis and prediction of AD", J Clin Med, 8, pp.341~ (2019)
22. Scheltens P, "A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging", J Neurol Sci, 114, pp.7~12 (1993)
23. Fazekas F, "MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging", AJR Am J Roentgenol, 149, pp.351~356 (1987)
24. Noh Y, "A new classification system for ischemia using a combination of deep and periventricular white matter hyperintensities", J Stroke Cerebrovasc Dis, 23, pp.636~642 (2014)
25. Moon S, "The Korea Biobank Array: Design and Identification of Coding Variants Associated with Blood Biochemical Traits", Sci Rep, 9, pp.1382~ (2019)
26. 김도윤, "Different Location of Triaxial Accelerometer and Different Energy Expenditures", Yonsei Medical Journal, 55(4), pp.1145~1151 (2014), 연세대학교의과대학[DOI]
27. Shin DW, "Enhancing physical activity and reducing obesity through smartcare and financial incentives: a pilot randomized trial", Obesity (Silver Spring), 25, pp.302~310 (2017)
28. Lee JA, "Missing value imputation for physical activity data measured by accelerometer", Stat Methods Med Res, 27, pp.490~506 (2018)
29. Witting W, "Alterations in the circadian rest-activity rhythm in aging and Alzheimer’s disease", Biol Psychiatry, 27, pp.563~572 (1990)
30. Takashima A, "Establishment of fibroblast cultures", Curr Protoc Cell Biol (2001)
31. Vangipuram M, "Skin punch biopsy explant culture for derivation of primary human fibroblasts", J Vis Exp, (77), pp.e3779~ (2013)
32. Yang S, "Assessment of circadian function in fibroblasts of patients with bipolar disorder", Mol Psychiatry, 14, pp.143~155 (2009)
33. Ossenkoppele R, "Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis", JAMA, 313, pp.1939~1949 (2015)
34. Corbo RM, "Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele?", Ann Hum Genet, 63, pp.301~310 (1999)
35. Crean S, "Apolipoprotein E epsilon4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysis", Dement Geriatr Cogn Disord, 31, pp.20~30 (2011)
36. Ward A, "Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4", 4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis, 2012, pp.38, 1~17
37. Leng Y, "Association between circadian rhythms and neurodegenerative diseases", Lancet Neurol, 18, pp.307~318 (2019)
38. Roh HW, "Associations of rest-activity patterns with amyloid burden, medial temporal lobe atrophy, and cognitive impairment", EBioMedicine, 58, pp.102881~ (2020)
39. Palmer JR, "Rest-activity functioning is related to white matter microarchitecture and modifiable risk factors in older adults at-risk for dementia", Sleep, 44, pp.zsab007~ (2021)
40. 구본상, "Past, Present, and Future of Brain Organoid Technology", Molecules and Cells, 42(9), pp.617~627 (2019), 한국분자세포생물학회[DOI]
41. Arber C, "Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer’s disease and dementia", J Neurochem, 159, pp.305~317 (2021)
42. Brown SA, "The period length of fibroblast circadian gene expression varies widely among human individuals", PLoS Biol, 3, pp.e338~ (2005)

관련 논문AI추천